Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16234266 | 0.87 | CES2 (0.46) | CES2IDO1MAPTKIF11AR | |
| SCHEMBL186842 | 0.87 | GABRA1 (0.52) | GABRA1GABRB2CES2PTGS1IDO1 | |
| SCHEMBL18353568 | 0.86 | GABRA1 (0.76) | GABRA1GABRB2CES2PTGS1IDO1 | |
| SCHEMBL29005991 | 0.85 | GABRA1 (0.50) | GABRA1GABRB2CES2PTGS1IDO1 | |
| Water SCHEMBL21493255 | 0.85 | GABRA1 (0.50) | GABRA1GABRB2CES2PTGS1IDO1 | |
| SCHEMBL29384937 | 0.85 | GABRA1 (0.50) | GABRA1GABRB2CES2PTGS1IDO1 | |
| SCHEMBL29886876 | 0.85 | CES2 (0.56) | GABRA1GABRB2CES2PTGS1IDO1 | |
| SCHEMBL29170632 | 0.82 | CES2 (0.48) | GABRA1GABRB2CES2PTGS1IDO1 | |
| SCHEMBL69029 | 0.82 | PTGS1 (0.52) | GABRA1GABRB2CES2PTGS1IDO1 | |
| SCHEMBL15077166 | 0.80 | GABRB2 (0.46) | GABRA1GABRB2CES2IDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | GABRA1 380/4885GABRB2 539/4885CES2 3315/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | GABRA1 442/4885GABRB2 492/4885CES2 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.